Appendicies

A Estimands

 ${\bf Table~S1.}~{\rm Estimands~of~the~observational~study~emulating~target~trial}$

Estimand component	Description	
Estimand 1		
Population	Adults with non-valvular atrial fibrillation receiving	
	anticoagulants meeting eligibility criteria	
Variable of interest	Composite of stroke (Ischemic or hemorrhagic) or	
	systemic embolism	
Treatments	Apixaban $(2.5/5 \text{ mg})$ versus Warfarin adjusted to target	
	an INR of $(2.0-3.0)$	
Population level summary	BMI stratum specific Risk ratios and Risk differences	
Intercurrent events	1- Treatment discontinuation (treatment policy strategy)	
(strategies to handle them)	2- Treatment switching (treatment policy strategy)	
Estimand 2		
Population	Adults with non-valvular atrial fibrillation receiving	
	anticoagulants meeting eligibility criteria	
Variable of interest	Major bleeding	
Treatments	Apixaban (2.5/5 mg) versus Warfarin adjusted to target	
	an INR of $(2.0-3.0)$	
Population level summary	BMI stratum specific Risk ratios and Risk differences	
Intercurrent events	1- Treatment discontinuation (hypothetical strategy) 2-	
(strategies to handle them)	Treatment switching (hypothetical policy strategy)	
Estimand 3		
Population	Adults with non-valvular atrial fibrillation receiving	
	anticoagulants meeting eligibility criteria	
Variable of interest	Ischemic or hemorrhagic stroke	
Treatments	Apixaban $(2.5/5 \text{ mg})$ versus Warfarin adjusted to target	
	an INR of (2.0-3.0)	

Population level summary Intercurrent events Intercurrent events Intercurrent events Intercurrent events Intercurrent events I- Treatment discontinuation (treatment policy strategy) 2- Treatment switching (treatment policy strategy) Estimand 4 Population Adults with non-valvular atrial fibrillation receiving anticoagulants meeting eligibility criteria Variable of interest Ischemic stroke Treatments Apixaban (2.5/5 mg) versus Warfarin adjusted to target an INR of (2.0-3.0) Population level summary Intercurrent events Intercurrent events Intercurrent discontinuation (treatment policy strategy)
Estimand 4 Population Adults with non-valvular atrial fibrillation receiving anticoagulants meeting eligibility criteria Variable of interest Ischemic stroke Treatments Apixaban (2.5/5 mg) versus Warfarin adjusted to target an INR of (2.0-3.0) Population level summary BMI stratum specific Risk ratios and Risk differences Intercurrent events 1- Treatment discontinuation (treatment policy strategy)
Estimand 4 Population Adults with non-valvular atrial fibrillation receiving anticoagulants meeting eligibility criteria Variable of interest Ischemic stroke Treatments Apixaban (2.5/5 mg) versus Warfarin adjusted to target an INR of (2.0-3.0) Population level summary BMI stratum specific Risk ratios and Risk differences Intercurrent events 1- Treatment discontinuation (treatment policy strategy)
Population Adults with non-valvular atrial fibrillation receiving anticoagulants meeting eligibility criteria Variable of interest Ischemic stroke Treatments Apixaban (2.5/5 mg) versus Warfarin adjusted to target an INR of (2.0-3.0) Population level summary BMI stratum specific Risk ratios and Risk differences Intercurrent events 1- Treatment discontinuation (treatment policy strategy)
Variable of interest Ischemic stroke Treatments Apixaban (2.5/5 mg) versus Warfarin adjusted to target an INR of (2.0-3.0) Population level summary BMI stratum specific Risk ratios and Risk differences Intercurrent events 1- Treatment discontinuation (treatment policy strategy)
Variable of interest Ischemic stroke Apixaban (2.5/5 mg) versus Warfarin adjusted to target an INR of (2.0-3.0) Population level summary BMI stratum specific Risk ratios and Risk differences Intercurrent events 1- Treatment discontinuation (treatment policy strategy)
Treatments Apixaban (2.5/5 mg) versus Warfarin adjusted to target an INR of (2.0-3.0) Population level summary BMI stratum specific Risk ratios and Risk differences Intercurrent events 1- Treatment discontinuation (treatment policy strategy)
an INR of (2.0-3.0) Population level summary BMI stratum specific Risk ratios and Risk differences Intercurrent events 1- Treatment discontinuation (treatment policy strategy)
Intercurrent events 1- Treatment discontinuation (treatment policy strategy)
(1 0 00/
(strategies to handle them) 2- Treatment switching (treatment policy strategy)
Estimand 5
Population Adults with non-valvular atrial fibrillation receiving
anticoagulants meeting eligibility criteria
Variable of interest Hemorrhagic stroke
Treatments Apixaban $(2.5/5 \text{ mg})$ versus Warfarin adjusted to target
an INR of $(2.0-3.0)$
Population level summary BMI stratum specific Risk ratios and Risk differences
Intercurrent events 1- Treatment discontinuation (treatment policy strategy)
(strategies to handle them) 2- Treatment switching (treatment policy strategy)
Estimand 6
Population Adults with non-valvular atrial fibrillation receiving
anticoagulants meeting eligibility criteria
anticoagulants meeting eligibility criteria
anticoagulants meeting eligibility criteria Variable of interest Systemic embolism

Intercurrent events	1- Treatment discontinuation (treatment policy strategy)
(strategies to handle them)	2- Treatment switching (treatment policy strategy)
Estimand 7	
Population	Adults with non-valvular atrial fibrillation receiving
	anticoagulants meeting eligibility criteria
Variable of interest	Mortality
Treatments	Apixaban $(2.5/5 \text{ mg})$ versus Warfarin adjusted to target
	an INR of $(2.0-3.0)$
Population level summary	BMI stratum specific Risk ratios and Risk differences
Intercurrent events	1- Treatment discontinuation (treatment policy strategy)
(strategies to handle them)	2- Treatment switching (treatment policy strategy)
Estimand 8	
Population	Adults with non-valvular atrial fibrillation receiving
	anticoagulants meeting eligibility criteria
Variable of interest	Composite of stroke (Ischemic or hemorrhagic) or
	systemic embolism
Treatments	Apixaban $(2.5/5 \text{ mg})$ versus Warfarin adjusted to target

an INR of (2.0-3.0)

BMI stratum specific Risk ratios and Risk differences

Treatment switching (hypothetical policy strategy)

1- Treatment discontinuation (hypothetical strategy) 2-

Population level summary

(strategies to handle them)

Intercurrent events

B Target trial protocol

Table S2. Brief protocol of target trial emulation

Protocol	ARISTOTLE	Target trial	Observational
component			analysis
Eligibility	Inclusion criteria	- Same as ARISTOTLE apart	- Same as target
criteria	- Age \geq 18 y between December	from:	trial apart from:
	19, 2006, through April 2, 2010	- Study period from	- No informed
	- Permanent or persistent AF or	01/01/2013 to $31/07/2019$	consent is required
	atrial flutter on ECG at	- Only in patients from	but patients might
	enrollment; or AF or atrial	England with EHR in CPRD	opt-out of data
	flutter documented by ECG or	Aurum and linkage to HES	sharing
	as an episode ≥ 1 min on	and ONS linked patients.	
	rhythm strip, Holter monitor, or	- Registered with a practice	
	intracardiac recording on 2	contributing research quality	
	separate occasions at least 2	data for at least 6 months on	
	week apart in 12 months before	or prior to the index date.	
	enrollment	- Permanent or persistent AF	
	- One or more of the following	documentation using ECG is	
	risk factors for stroke:	not assessed	
	$\mathrm{Age} \geq 75~\mathrm{y}$	- Three additional stroke risk	
	Prior stroke, TIA, or systemic	factors: Age 64-75, female	
	embolus	and vascular disease (i.e.	
	Symptomatic CHF within 3 mo	$\mathrm{CHA_2DS_2}\text{-VASc}$ instead of	
	or LV dysfunction with LVEF \leq	CHADS 2)	
	40% by echocardiography,		
	radionuclide study, or contrast		
	angiography		
	Diabetes mellitus		
	Hypertension requiring		
	pharmacologic treatment		

Protocol	ARISTOTLE	Target trial	Observational
component			analysis
	- Women of childbearing	- No contraception is required	
	potential must use contraception	from women of childbearing	
	to avoid pregnancy during	age but any women with	
	treatment period or for 2 wk	history of breastfeeding or	
	after last dose of study	pregnancy in last two years	
	medication, whichever is longer	prior to index date was	
	- All subjects must provide	excluded	
	signed written informed consent	- No assessment of planned	
	- Exclusion criteria	procedure	
	- AF or atrial flutter due to	- No exclusion for: - Patients	
	reversible causes	with presesitant uncontrolled	
	- Clinically significant (moderate	hypertension	
	or severe) mitral stenosis	- Severe comorbid condition	
	- Increased bleeding risk believed	with life expectancy ≤ 1 year	
	to be a contraindication to oral	- Active alcohol or drug abuse	
	anticoagulation (eg, previous	or psychosocial reasons that	
	intracranial hemorrhage)	make study participation	
	- Conditions other than AF that	impractical	
	require chronic anticoagulation	- No assessment of planned	
	(eg, prosthetic mechanical heart	procedure	
	valve)	- No exclusion for: - Patients	
	- Persistent uncontrolled	with presesitant uncontrolled	
	hypertension (SBP 180mmHg	hypertension	
	or DBP 100mmHg)		
	- Active infective endocarditis		

$egin{array}{c} { m Protocol} \\ { m component} \end{array}$	ARISTOTLE	Target trial	Observational analysis
	- Planned major surgery	- Severe comorbid condition	
	- Planned AF or atrial flutter	with life expectancy ≤ 1 year	
	ablation procedure	- Active alcohol or drug abuse	
	- Use of unapproved	or psychosocial reasons that	
	investigational drug or device in	make study participation	
	past 30 days	impractical	
	- Required aspirin 165 mg/d	- Severe renal insufficiency	
	- Simultaneous treatment with	(serum creatinine level 2.5	
	both aspirin and a	mg/dL or calculated	
	thienopyridine (eg, clopidogrel,	creatinine clearance <25	
	ticlopidine)	$\mathrm{mL/min})$	
	- Severe comorbid condition	- ALT or AST $2 \times$ ULN or a	
	with life expectancy ≤ 1 year	total bilirubin \geq 1.5 × ULN	
	- Active alcohol or drug abuse or	(unless an alternative	
	psychosocial reasons that make	causative factor [eg, Gilbert's	
	study participation impractical	syndrome] is identified)	
	- Recent stroke (within 7 days)	- Platelet count \leq	
	- Severe renal insufficiency	$100,000/{\rm mm}^3$	
	(serum creatinine level 2.5	- Hemoglobin level <9 g/dL	
	mg/dL or calculated creatinine	- No assessment of use of	
	${\rm clearance} < \! 25~{\rm mL/min})$	unapproved investigational	
	- ALT or AST $2 \times$ ULN or a	drug or device in past 30 days	
	total bilirubin \geq 1.5 \times ULN	Any history of symptomatic	
	(unless an alternative causative	CHF or LV dysfunction	
	factor [eg, Gilbert's syndrome]	- No assessment of inability to	
	is identified)	comply with INR monitoring	
	- Platelet count $\leq 100,000/\mathrm{mm}^3$		
	- Hemoglobin level <9 g/dL		
	- Inability to comply with INR		
	monitoring		

Protocol	ARISTOTLE	Target trial	Observational
component			analysis
Treatment	1- Starting Apixaban or	1- Same as ARISTOTLE	Same as target
strategies	matching placebo twice daily,		trial
	with apixaban given in 5-mg		
	doses; 2.5-mg doses were used in		
	a subset of patients with two or		
	more of the following criteria:		
	- an age of at least 80 years,		
	- a body weight of no more than		
	60 kg, or		
	- a serum creatinine level of 1.5		
	mg per deciliter (133 μmol per		
	liter) or more.		
	2- Warfarin (or matching	2- Warfarin tablets adjusted	Same as target
	placebo) as 2-mg tablets	to achieve a target	trial
	adjusted to achieve a target	international normalized ratio	
	international normalized ratio	(INR) of 2.0 to 3.0. – Did not	
	(INR) of 2.0 to 3.0. Patients	include patients already	
	who are already receiving a	reciving vitamin K	
	vitamin K antagonist before	antagonists so no washout	
	randomization were instructed	period	
	to discontinue the drug 3 days		
	before randomization, and the		
	study drug was initiated when		
	the INR was less than 2.0.		

Protocol	ARISTOTLE	Target trial	Observational
component			analysis
Assignment	Participants will be randomized	Participants will be	Participants'
procedure	to a treatment strategy while	randomized to a treatment	strategies were
	not being aware of the assigned	strategy and are aware of the	classified
	strategy	assigned strategy	according to the
			observed data at
			baseline while
			adjusting for the
			confounders using
			inverse probability
			treatment
			weighting to
			emulate
			randomization

Protocol component	ARISTOTLE	Target trial	Observational analysis
Outcomes	Efficacy outcomes:	Same as ARISTOTLE away	Same as target
	The primary efficacy outcome is:	from:	trial
	- Time to first occurrence of	- Myocardial infarction, any	Outcomes
	stroke (ischemic or	bleeding, other adverse events,	recorded using
	haemorrhagic) or systemic	and liver-function	ICD-10 codes
	embolism.	abnormalities will not be	
	The key secondary efficacy	assessed	
	outcomes:		
	- death from any cause.		
	- rate of myocardial infarction		
	Safety outcomes:		
	- Major bleeding,		
	- Composite of major bleeding		
	and clinically relevant nonmajor		
	bleeding.		
	- Any bleeding, other adverse		
	events, and liver-function		
	abnormalities		
Follow-up	Start at randomization and ends	Same as ARISTOTLE	Same as target
period	at the earliest of death,		apart from
	withdrawal of consent to be		withdrawal of
	followed-up, loss to follow-up or		consent
	the study end date.		
Causal	Intention-to-treat for efficacy	A treatment policy estimand	Observational
contrasts of	and safety population for safety	for effectivness and a	analogue of
interest		hypotheical estimand for major bleeding	specifed estimano

Protocol	ARISTOTLE	Target trial	Observational
component			analysis
Statistical	- Non-inferiority hypothesis	- Same as ARISTOTLE apart	Same as target
analysis	required that apixaban upper	from:	trial with
plan	boundary of the 95% confidence	- Geographic region will not	adjustment for
	interval for the relative risk	be used as strata in the	baseline
	would be less than 1.38 for	model.	confounders using
	primary efficacy outcome	- The analysis will be stratifed	inverse probability
	- Relative risk was calculated	by BMI groups	treatment
	using Cox proportional-hazards	- No subgroup analyses.	weighting and for
	model, with previous warfarin	Risk ratios and risk	ceonsring inverse
	status and geographic region	differences will be estimated	probability
	used as strata in the model.	through a weighted IPW	censoring
	- Event rates will be estimated	estimator that coincides with	weighting in each
	and plotted over time using	Aalen-Johansen estimator for	outcome
	Kaplan-Meier methodology.	total effects and a weighted	
	- Subgroup analyses:	Kaplan-Meier estimator for	
	- Prior warfarin/VKA status -	direct effects	
	Apixaban dose - Geographic	Cumulative incidence	
	Region - Age - Gender - Race -	figures will be reported	
	Ethnicity - Weight - Level of	Non-inferiority margin will	
	Renal Impairment - Number of	not be used due to differences	
	risk factors - CHADS2 Score -	in study population	
	Prior Stroke or TIA - Age ≥ 75		
	- Diabetes Mellitus -		
	Hypertension requiring		
	pharmacological treatment -		
	Heart Failure - Aspirin at		
	randomization		

C Variables

Table S3. Variables definition in the study

Variables	Definition	Levels (form used in analysis)	Data source	Outcome ICD-10 Codes
Treatments	First prescription of study treatments	 Apixaban; Warfarin 	CPRD Aurum	
Stroke/SE	First event of stroke or systemic embolism during follow-up	0: No; 1: Yes	HES APC	I60.1, I60.2, I60.3, I60.4, I60.5, I60.6, I60.7, I60.8, I60.9, I61.0, I61.1, I61.2, I61.3, I61.4, I61.5, I61.6, I61.7, I61.8, I61.9, I62.0, I62.1, I62.9, I63.0, I63.1, I63.2, I63.3, I63.4, I63.5, I63.6, I63.8, I63.9, I64, I74.0, I74.1, I74.2, I74.3, I74.4, I74.5, I74.8, I74.9

Variables	Definition	Levels (form used	Data source	Outcome ICD-10 Codes
		in analysis)		
Stroke (any	First event of	0: No; 1: Yes	HES APC	I60.1, I60.2, I60.3,
type)	is-			I60.4, I60.5, I60.6,
	chemic/hemorr	ghic		I60.7, I60.8, I60.9,
	stroke during			I61.0, I61.1, I61.2,
	follow-up			I61.3, I61.4, I61.5,
				I61.6, I61.7, I61.8,
				I61.9, I62.0, I62.1,
				I62.9, I63.0, I63.1,
				I63.2, I63.3, I63.4,
				I63.5, I63.6, I63.8,
				I63.9, I64
Ischemic	First event of	0: No; 1: Yes	HES APC	I63.0, I63.1, I63.2,
stroke	ischemic			163.3, 163.4, 163.5,
	stroke during			I63.6, I63.8, I63.9, I64
	follow-up			
Hemorrghic	First event of	0: No; 1: Yes	HES APC	I60.1, I60.2, I60.3,
stroke	hemorrghic			I60.4, I60.5, I60.6,
	stroke during			I60.7, I60.8, I60.9,
	follow-up			I61.0, I61.1, I61.2,
				I61.3, I61.4, I61.5,
				I61.6, I61.7, I61.8,
				I61.9, I62.0, I62.1,
				I62.9

(continued)

Variables	Definition	Levels	Data source	Outcome ICD-10
		(form used		Codes
		in analysis)		
Systematic	First event of	0: No; 1: Yes	HES APC	I74.0, I74.1, I74.2,
embolism	systemic			174.3, 174.4, 174.5,
	embolism			174.8, 174.9
	during			
	follow-up			

Variables	Definition	Levels	Data source	Outcome ICD-10
		(form used		Codes
		in analysis)		
Major	First event of	0: No; 1: Yes	HES APC	D68.3, H35.6 H43.1,
bleeding	major			H45.0, I60.0, I60.1,
	bleeding			I60.2, I60.3, I60.4,
	during			I60.5, I60.6, I60.7,
	follow-up			I60.8, I60.9, I61.0,
				I61.1, I61.2, I61.3,
				I61.4, I61.5, I61.6,
				I61.8, I61.9, I62.0,
				I62.1, I62.9, I85.0,
				I98.3, K25.0, K25.2,
				K25.4, K25.6, K26.0,
				K26.2, K26.4, K26.6,
				K27.0, K27.4, K27.6,
				K28.0, K28.2, K28.4,
				K28.6, K29.0, K62.5,
				K66.1, K92.0, K92.1,
				K92.2, M25.0, N02.0,
				N02.1, N02.2, N02.3,
				N02.4, N02.5, N02.7,
				N02.8, N02.9, N93.8,
				N93.9, N95.0, R04.1,
				R04.2, R04.8, R04.9,
				R58
Death	Death within follow-up	0: No; 1: Yes	ONS	
	period			

Variables	Definition	Levels (form used in analysis)	Data source	Outcome ICD-10 Codes
Age	Patient age at enrollment assuming mid year birth	Numeric (Linear, quadratic)	CPRD Aurum	
Gender	Patient gender	1: Male; 2: Female	CPRD Aurum	
Individual level index of multiple deprivation (2015)	Individual so- cioeconmoic status mapped to postcode of residence according to 2015 English Index of Multiple Deprivation	1 (least deprived), 2, 3, 4, 5 (most deprived)	CPRD Aurum	
Practice level index of multiple deprivation (2015)	Practice so- cioeconmoic status mapped to postcode according to 2015 English Index of Multiple	1 (least deprived), 2, 3, 4, 5 (most deprived)	CPRD Aurum	

Variables	Definition	Levels (form used in analysis)	Data source	Outcome ICD-10 Codes
BMI	Lat observation prior to index date	Numeric	CPRD Aurum	
BMI groups	Grouped BMI	1:Normal weight; 2:Overweight; 3:Obese	CPRD Aurum	
Smoking status	Any history at baseline	1:Non-smoker; 2:Ex-smoker; 3:Current-smoker	CPRD Aurum	
Alcohol	Alcohol consumption at baseline	1:Non- drinker; 2:Light- drinker; 3:Moderate- drinker; 4:Heavy- drinker	CPRD Aurum	
Ethinic groups	Ethnic group	1:Black; 2:East Asian; 3:Mixed; 4:Other; 5: South Asian; 6:White	CPRD Aurum	

Variables	Definition	Levels (form used in analysis)	Data source	Outcome ICD-10 Codes
Renal	Renal	1:Normal;	CPRD	
function	function	2:Mild	Aurum	
	based on last	impairment;		
	creatinine	3:Moderate		
	clearance	impairment;		
	measurement	4:Severe		
	prior to index	impairment		
	date			
Index year	Year of first	1:2013;	CPRD	
	prescription	2:2014;	Aurum	
	of study	3:2015;		
	treatments	4:2016;		
		5:2017;		
		6:2018;		
		7:2019		
Prior stroke	Any history	0: No; 1: Yes	CPRD	
	at baseline		Aurum and	
			HES APC	
Prior	Any history	0: No; 1: Yes	CPRD	
transient	at baseline		Aurum and	
ischemic			HES APC	
attack				
Prior	Any history	0: No; 1: Yes	CPRD	
systemic	at baseline		Aurum and	
embolism			HES APC	

Variables	Definition	Levels	Data source	Outcome ICD-10
		(form used		Codes
		in analysis)		
Congestive	Any history	0: No; 1: Yes	CPRD	
heart failure	at baseline or		Aurum and	
or left	LVEF value		HES APC	
ventricular	less than or			
dysfunction	equal to 40%			
(LVEF)				
Diabetes	Any history	0: No; 1: Yes	CPRD	
	at baseline		Aurum	
Hypertension	Any history	0: No; 1: Yes	CPRD	
requrieing	at baseline		Aurum	
treatment				
History of	Any history	0: No; 1: Yes	CPRD	
Prephiral	at baseline		Aurum and	
artery disease			HES APC	
History of	Any history	0: No; 1: Yes	CPRD	
Aortic plauge	at baseline		Aurum and	
			HES APC	
History of	History prior	0: No; 1: Yes	CPRD	
non-major	to index date		Aurum and	
bleeding			HES APC	
History of	Any recored	0: No; 1: Yes	CPRD	
myocardial	in patient file		Aurum and	
Infarction	at baseline		HES APC	
History of	Any recored	0: No; 1: Yes	CPRD	
Chronic	in patient file		Aurum and	
obstructive	at baseline		HES APC	
disease				

Variables	Definition	Levels	Data source	Outcome ICD-10
		(form used		Codes
		in analysis)		
History of	Any recored	0: No; 1: Yes	CPRD	
Liver disease	in patient file		Aurum and	
	at baseline		HES APC	
History of	Any recored	0: No; 1: Yes	CPRD	
Hematologi-	in patient file		Aurum and	
cal cancer	at baseline		HES APC	
History of	Any recored	0: No; 1: Yes	CPRD	
History of	in patient file		Aurum and	
valve surgury	at baseline		HES APC	
History of	Any recored	0: No; 1: Yes	CPRD	
Connective	in patient file		Aurum and	
tissue	at baseline		HES APC	
diseases				
History of	Any recored	0: No; 1: Yes	CPRD	
Hemiplegia	in patient file		Aurum and	
	at baseline		HES APC	
History of	Any recored	0: No; 1: Yes	CPRD	
Peptic ulcer	in patient file		Aurum and	
	at baseline		HES APC	
History of	Any recored	0: No; 1: Yes	CPRD	
solid cancer	in patient file		Aurum and	
diagnosis	at baseline		HES APC	
History of	Any recored	0: No; 1: Yes	CPRD	
valvular	in patient file		Aurum and	
disease	at baseline		HES APC	


Variables	Definition	Levels	Data source	Outcome ICD-10
		(form used		Codes
		in analysis)		
Use of	Concomitant	0: No; 1: Yes	CPRD	
Amiodarone	use at		Aurum	
	baseline			
Use of aspirin	Concomitant	0: No; 1: Yes	CPRD	
	use at		Aurum	
	baseline			
Use of	Concomitant	0: No; 1: Yes	CPRD	
antacids	use at		Aurum	
	baseline			
Use of	Concomitant	0: No; 1: Yes	CPRD	
Angiotensin-	use at		Aurum	
converting	baseline			
enzyme				
inhibitors and				
angiotensin II				
receptor				
blockers				
Use of	Concomitant	0: No; 1: Yes	CPRD	
beta-blocker	use at		Aurum	
	baseline			
Use of	Concomitant	0: No; 1: Yes	CPRD	
Clopidogrel	use at		Aurum	
	baseline			
Use of	Concomitant	0: No; 1: Yes	CPRD	
digoxin	use at		Aurum	
	baseline			

(continued)

Variables	Definition	Levels (form used in analysis)	Data source	Outcome ICD-10 Codes
Use of non-steroidal anti- inflammatory drugs	Concomitant use at baseline	0: No; 1: Yes	CPRD Aurum	
Use of Statins	Concomitant use at baseline	0: No; 1: Yes	CPRD Aurum	


 $\mathbf{BMI:}$ Body mass Index

D Directed acyclic graphs




 CHA_2DS_2 -VASc: Congestive heart failure, hypertension, age ≥ 75 , diabetes mellitus, prior stroke, transient ischaemic attack or thromboembolism, vascular disease (peripheral artery disease, myocardial infarction, aortic plaque), age 65 to 74 and sex category (female); ACEIs: Angiotensin-converting enzyme inhibitors; ARBs: Angiotensin receptor blockers; BMI: Body mass index, an effect modifier by proxy

Figure S1. Directed acyclic graph for stroke, systemic embolism outcomes



Components of ORBIT and HAS-BLED Scores: Low hemoglobin or hematocrit, age > 74 years, any history of GI bleeding, intracranial bleeding, or hemorrhagic stroke, Glomerular filtration rate < 60 mL/min/1.73 m², using antiplatelet agents (Aspirin, clopidogrel, NSAIDs), hypertension, liver disease and alcohol use; **BMI:** Body mass index, an effect modifier by proxy

Figure S2. Directed acyclic graph for major bleeding



CHA₂DS₂-VASc: Congestive heart failure (CHF), hypertension, age ≥ 75, Diabetes mellitus (DM), prior stroke, transient ischaemic attack (TIA) or thromboembolism, vascular disease (peripheral artery disease (PAD), Myocardial infarction (MI), aortic plaque), age 65 to 74 and sex category (female); **Charlson comorbidity index:** Age, MI, CHF, PAD, prior stroke or TIA, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, DM, hemiplegia, chronic kidney disease, solid tumor, leukemia and lymphoma; **BMI:** Body mass index, an effect modifier by proxy

Figure S3. Directed acyclic graph for mortality

Table S4. Baseline characteristics of eligible study participants using CPRD linked data by treatment group with unweighted and inverse probability treatment weighted standardised mean differences

Characteristics	Apixaban	Warfarin	Overall	Unweighted SMD	$\begin{array}{c} \text{IPT} \\ \text{weighted} \\ \text{SMD} \end{array}$
Number of patients (N)	27747	23145	50892		SMD
Demographics					
Age at entry	78.00	77.00	78.00	0.149	0.042
(years)-median [IQR]	[71.00,	[71.00,	[71.00,		
	84.00]	82.00]	83.00]		
Age groups at entry (years)-N (%)				0.072	0.097
18-49	118 (0.4)	116 (0.5)	234 (0.5)		
50-59	744 (2.7)	673 (2.9)	1417 (2.8)		
60-69	3545 (12.8)	3383 (14.6)	6928 (13.6)		
70-74	5397 (19.5)	4776 (20.6)	10173		
			(20.0)		
≥ 75	17943	14197	32140		
	(64.7)	(61.3)	(63.2)		
Female- N (%)	13079	10363	23442	0.047	0.008
	(47.1)	(44.8)	(46.1)		
$\mathbf{Weight} \text{ (kg)- median [IQR]}$	79.00	81.00	80.00	0.111	0.132
	[67.00,	[69.60,	[68.00,		
	92.00]	94.00]	93.00]		
${f BMI}$ (kg/m ²)- median [IQR]	27.80	28.30	28.00	0.087	0.133
	[24.60,	[25.00,	[24.80,		
	31.80]	32.32]	32.00]		
BMI groups (kg/m ²)- N (%)				0.088	0.120

Characteristics	Apixaban	Warfarin	Overall	Unweighted SMD	$\begin{array}{c} \text{IPT} \\ \text{weighted} \\ \text{SMD} \end{array}$
Underweight <18.5	438 (1.6)	245 (1.1)	683 (1.3)		
Normal weight 18.5-24.9	7231 (26.1)	5446 (23.5)	12677 (24.9)		
Overweight 25-29.9	10280 (37.0)	8561 (37.0)	18841 (37.0)		
Obesity class I 30-34.9	6065 (21.9)	5368 (23.2)	11433 (22.5)		
Obesity class II 35-39.9	2396 (8.6)	2228 (9.6)	4624 (9.1)		
Obesity class III ≥ 40	1337 (4.8)	1297 (5.6)	2634 (5.2)		
Individual-level IMD(2015)- N (%)				0.044	0.029
1st quintile (Least deprived)	6924 (25.0)	5529 (23.9)	12453 (24.5)		
2nd quintile	6446 (23.2)	5346 (23.1)	11792 (23.2)		
3rd quintile	5401 (19.5)	4692 (20.3)	10093 (19.8)		
4th quintile	4638 (16.7)	4132 (17.9)	8770 (17.2)		
5th quintile (Most deprived)	4338 (15.6)	3446 (14.9)	7784 (15.3)		
Practice-level IMD(2015)- N $(\%)$				0.054	0.021
1st quintile (Least deprived)	5342 (19.3)	4285 (18.5)	9627 (18.9)		

Characteristics	Apixaban	Warfarin	Overall	Unweighted SMD	$\begin{array}{c} \text{IPT} \\ \text{weighted} \\ \text{SMD} \end{array}$
2nd quintile	5704 (20.6)	4573 (19.8)	10277 (20.2)		
3rd quintile	5205 (18.8)	4822 (20.8)	10027 (19.7)		
4th quintile	6021 (21.7)	4922 (21.3)	10943 (21.5)		
5th quintile (Most deprived)	5475 (19.7)	4543 (19.6)	10018 (19.7)		
Ethnicity- N (%)				0.023	0.022
Black	276 (1.0)	283 (1.2)	559 (1.1)		
East Asian	37 (0.1)	31 (0.1)	68 (0.1)		
Mixed	62 (0.2)	52 (0.2)	114 (0.2)		
Other	71 (0.3)	53 (0.2)	124 (0.2)		
South Asian	524 (1.9)	445 (1.9)	969 (1.9)		
White	26777 (96.5)	22281 (96.3)	49058 (96.4)		
Lifestyle factors- N (%)					
Smoking status				0.055	0.008
Non-smoker	10190 (36.7)	7942 (34.3)	18132 (35.6)		
Former smoker	15550 (56.0)	13589 (58.7)	29139 (57.3)		
Current smoker	2007 (7.2)	1614 (7.0)	3621 (7.1)		

Characteristics	Apixaban	Warfarin	Overall	Unweighted SMD	IPT weighted SMD
Alcohol consumption				0.060	0.017
Non-drinker	10631 (38.3)	8453 (36.5)	19084 (37.5)		
Light drinker	12972 (46.8)	11425 (49.4)	24397 (47.9)		
Moderate	3537 (12.7)	2872 (12.4)	6409 (12.6)		
Heavy	607 (2.2)	395 (1.7)	1002 (2.0)		
Disease charactir sitcis- N $(\%)$					
$\mathrm{CHA_2DS_2} ext{-VASc}$ components					
Congestive heart failure (or left ventricular systolic dysfunction)	6529 (23.5)	5164 (22.3)	11693 (23.0)	0.029	0.018
Treated hypertension	21451 (77.3)	17969 (77.6)	39420 (77.5)	0.008	0.002
Systolic blood pressure (mm Hg)- median [IQR]	132.00 [121.00, 142.00]	132.00 [121.00, 140.00]	132.00 [121.00, 141.00]	0.016	0.002
Diabetes mellitus	8051 (29.0)	6663 (28.8)	14714 (28.9)	0.005	0.019
Stroke, TIA, or SE	7356 (26.5)	4928 (21.3)	12284 (24.1)	0.123	0.027

History of vascular

diseases

Characteristics	Apixaban	Warfarin	Overall	Unweighted SMD	$\begin{array}{c} \text{IPT} \\ \text{weighted} \\ \text{SMD} \end{array}$	
Peripheral artery disease	1803 (6.5)	1600 (6.9)	3403 (6.7)	0.017	0.019	
Aortic Plaque	5817 (21.0)	5053 (21.8)	10870 (21.4)	0.021	0.016	
Myocardial infarction	3582 (12.9)	3031 (13.1)	6613 (13.0)	0.006	0.010	
$\mathrm{CHA_2DS_2} ext{-VASc}$ score				0.114	0.051	
2	5956 (21.5)	5385 (23.3)	11341 (22.3)			
3	8221 (29.6)	7446 (32.2)	15667 (30.8)			
4	5750 (20.7)	4883 (21.1)	10633 (20.9)			
5	4342 (15.6)	3163 (13.7)	7505 (14.7)			
6	2297 (8.3)	1523 (6.6)	3820 (7.5)			
7	921 (3.3)	586 (2.5)	1507 (3.0)			
8	260 (0.9)	159 (0.7)	419 (0.8)			
Non-major bleeding	7806 (28.1)	5826 (25.2)	13632 (26.8)	0.067	0.016	
Fall in previous year	789 (2.8)	287 (1.2)	1076 (2.1)	0.114	0.041	
Comorbidities- N (%)						
Renal function				0.108	0.056	
Normal	7946 (28.6)	7607 (32.9)	15553 (30.6)			

Characteristics	Apixaban Warfar		Overall	Unweighted	IPT	
				SMD	weighted SMD	
					SWID	
Mild impairment	12093	9841 (42.5)	21934			
	(43.6)		(43.1)			
Moderate impairment	6307 (22.7)	4480 (19.4)	10787			
			(21.2)			
Severe impairment	1401 (5.0)	1217 (5.3)	2618 (5.1)			
Charlson comorbidity index						
components						
COPD	3820 (13.8)	2896 (12.5)	6716 (13.2)	0.037	0.030	
Connective tissue disease	1933 (7.0)	1471 (6.4)	3404 (6.7)	0.025	0.016	
Peptic ulcer disease	1485 (5.4)	1263 (5.5)	2748 (5.4)	0.005	0.024	
Liver disease	236 (0.9)	161 (0.7)	397 (0.8)	0.018	0.001	
Hemiplegia	86 (0.3)	42 (0.2)	128 (0.3)	0.026	0.016	
Non-hematological cancer	4385 (15.8)	3447 (14.9)	7832 (15.4)	0.025	0.009	
Hematological cancer	602 (2.2)	481 (2.1)	1083 (2.1)	0.006	0.006	
Concomitant medications at						
index date						
ACE inhibitors or ARBs	14083 (50.8)	12838 (55.5)	26921 (52.9)	0.095	0.011	
A.v.i. danana	,	, ,	, ,	0.000	0.000	
Amiodarone	482 (1.7)	485 (2.1)	967 (1.9)	0.026	0.008	
Antacids	719 (2.6)	598 (2.6)	1317(2.6)	0.001	0.002	
Aspirin	2274 (8.2)	3282 (14.2)	5556 (10.9)	0.191	0.036	
Beta-blockers	17429	14071	31500	0.042	0.009	
	(62.8)	(60.8)	(61.9)			

Characteristics	Apixaban	Warfarin	Overall	Unweighted	IPT
				SMD	weighted
					SMD
Calcium channel blockers	8800 (31.7)	7808 (33.7)	16608	0.043	0.044
			(32.6)		
Clopidogrel	996 (3.6)	1087 (4.7)	2083 (4.1)	0.056	0.010
Digoxin	2562 (9.2)	2345 (10.1)	4907 (9.6)	0.030	0.074
NSAIDs	2096 (7.6)	1487 (6.4)	3583 (7.0)	0.044	0.025
Statins	15867	13305	29172	0.006	0.008
	(57.2)	(57.5)	(57.3)		
Index year- N (%)				1.893	0.035
2013	170 (0.6)	7150 (30.9)	7320 (14.4)		
2014	1030 (3.7)	6297 (27.2)	7327 (14.4)		
2015	2920 (10.5)	4697 (20.3)	7617 (15.0)		
2016	4973 (17.9)	2672 (11.5)	7645 (15.0)		
2017	6623 (23.9)	1327 (5.7)	7950 (15.6)		
2018	7387 (26.6)	676 (2.9)	8063 (15.8)		
2019	4644 (16.7)	326 (1.4)	4970 (9.8)		

ACE inhibitors or ARBs: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers; BMI: Body mass Index; CHA₂DS₂-VASc score: calculated as 1 for each component expect for age ≥ 75 and history of stroke counted as 2; COPD: Chronic obstructive pulmonary disease;IMD(2015): Index of Multiple Deprivation 2015; IQR: Interquartile range; IPT weighted: Inverse probability treatment weighted; NSAIDs: Non-steroidal anti-inflammatory drugs; SMD: Standardised mean differences; SE: Systemic embolism; TIA: Transient ischemic attack

E Quantitative variables

The quantitative variables were age, systolic blood pressure, weight, and BMI.

Age (years) was reported as continuous variable and was also categorized into 18-49, 50-59, 60-69, 70-74, \leq 75. Unequal intervals were used since the disease is uncommon in younger ages and being more than 75 years constitutes a major reason for initiating anticoagulant treatment.

Systolic blood pressure, and weight were reported as continuous variables.

BMI (kg/m²) was reported as continuous variable and categorized based on NICE's classification⁷⁹:

• Underweight: less than 18.5

• Healthy weight: 18.5-24.9

• Overweight: 25-29.9

 \bullet Obesity class I: 30-34.9

• Obesity class II: 35-39.9

• Obesity class III: ≥ 40

However, based on the initial estimates of total participants in each BMI group across treatment groups, we regrouped the variable in the analysis to the following categories to avoid data sparsity:

• Healthy weight: ≤ 24.9

• Overweight: 25-29.9

• Obese: ≥ 30

F Inverse probability weights

We first identified the stabilized inverse probability treatment weights, SW^A, for each individual in our study population. The denominator is the probability that an individual received the observed treatment (A), given observed confounders (L). We used different numerators for overall and BMI-stratified results. For overall results, the numerator is the probability of receiving the observed treatment (A). For stratified results, the numerator is the probability of receiving the observed treatment (A) given the effect modifier (V).

• Overall analysis:

$$SW^{A}(V) = \frac{f(A)}{f(A|L,V)}$$

• Stratified analysis:

$$SW^{A}(V) = \frac{f(A|V)}{f(A|L,V)}$$

We then identified the stabilized inverse probability censoring weights, SW^C, for each individual in our study population. The denominator is the probability that an individual is not censored (C) given the observed treatment (A) and observed confounders (L). The numerator is the probability that the individual is not censored (C) given the observed treatment (A).

$$SW^C = \frac{f(C=0|A)}{f(C=0|A,L)}$$

We multiplied the weights from the two models to get the final weights SW^{A,C}. These were used to non-parametrically estimate the cause-specific cumulative incidence described in Young et. al.²⁰

$$SW^{A,C} = SW^A(V)XSW^C$$

 $\textbf{Table S5.} \ \, \textbf{Summary of the inverse probability weights for the composite effectiveness outcome of stroke/systemic embolism and major bleeding$

Inverse probability weights (IPW)	Apixaban		Warfarin			
	Min	Max	Mean	Min	Max	Mean
Composite of						
${\it stroke/systemic\ embolism}$						
Stabilized Inverse probability	0.53	65.98	1.21	0.43	22.87	0.82
treatment weights						
Stabilized Inverse probability	0.53	6.72	1.07	0.43	6.72	0.81
treatment weights (truncated to						
the 99th percentile)						
Stabilized Inverse probability	0.30	9.64	0.94	0.86	7.29	0.99
censoring weights						
Stabilized Inverse probability	0.34	2.14	0.92	0.86	2.14	0.99
censoring weight (truncated to						
the 99th percentile)						
Major bleeding						
Stabilized Inverse probability	0.53	64.9	1.20	0.43	23.44	0.82
treatment weights						
Stabilized Inverse probability	0.53	6.74	1.06	0.43	6.74	0.81
treatment weights (truncated to						
the 99th percentile)						
Stabilized Inverse probability	0.26	11.34	0.94	0.86	4.76	0.99
censoring weights						
	0.22	1.07	0.02	0.06	1.07	0.00
Stabilized Inverse probability	0.32	1.97	0.92	0.86	1.97	0.92
censoring weight (truncated to						
the 99th percentile)						

G Results of secondary effectiveness outcomes



Figure S4. Inverse probability weighted estimates of the 3-year BMI stratum-specific risks, risk differences per 100 people, and risk ratios of the comparative effectiveness for the total effect of apixaban versus warfarin in stroke (any type), ischemic stroke, haemorrhagic stroke, and systemic embolism using a complete-case analysis (Estimands 3,4,5,6)




Figure S5. Inverse probability weighted cumulative incidence of the 3-year risk of the total effect of apixaban versus warfarin in stroke (ischemic or haemorrhagic) stratified by BMI using a complete-case analysis (Estimand 3)




Figure S6. Inverse probability weighted cumulative incidence of the 3-year risk of the total effect of apixaban versus warfarin in ischemic stroke stratified by BMI using a complete-case analysis (Estimand 4)




Figure S7. Inverse probability weighted cumulative incidence of the 3-year risk of the total effect of apixaban versus warfarin in haemorrhagic stroke stratified by BMI using a complete-case analysis (Estimands 5)




Figure S8. Inverse probability weighted cumulative incidence of the 3-year risk of the total effect of apixaban versus warfarin in systemic embolism stratified by BMI using a complete-case analysis (Estimands 6)

H Supplementary and sensitivity analyses

H.1 Supplementary analysis




Figure S9. Inverse probability weighted estimates of the 3-year BMI stratum-specific risks, risk differences per 100 people, and risk ratios of the comparative effectiveness for the total effect of apixaban versus warfarin in stroke/systemic embolism using a complete-case analysis and a hypothetical estimand (Estimand 8)

H.2 Analysis restricted to patients with BMI measurements in the last 3 years prior study entry




Figure S10. Inverse probability weighted estimates of the 3-year BMI stratum-specific risks, risk differences per 100 people, and risk ratios of the comparative effectiveness for the total effect of apixaban versus warfarin in stroke/systemic embolism using a complete-case analysis for patients with available BMI measurements in the last 3 years prior study entry




Figure S11. Inverse probability weighted estimates of the 3-year BMI stratum-specific risks, risk differences per 100 people, and risk ratios of the comparative safety for the total effect of apixaban versus warfarin in major bleeding using a complete-case analysisfor patients with available BMI measurements in the last 3 years prior study entry

H.3 Direct effect with elimination of competing events





Figure S12. Inverse probability weighted estimates of the 3-year BMI stratum-specific risks, risk differences per 100 people, and risk ratios of the comparative effectiveness for the direct effect of apixaban versus warfarin in stroke/systemic embolism using a complete-case analysis



"Using stabilized weights from inverse probability treatment weighting (IPTW) and inverse probability censroing weighting (IPCW); "Risk from IPT and IPC weighted Kaplan-Meier estimator; BMI:Body mass index; IPW: Inverse probability weighting; No.: Number of individuals in the analysis; RR:Risk ratio; 95% CI: 95% confidence interval estimated from non-parametric bootstrapping using 500 samples

Figure S13. Inverse probability weighted estimates of the 3-year BMI stratum-specific risks, risk differences per 100 people, and risk ratios of the comparative safety for the direct effect of apixaban versus warfarin in major bleeding using a complete-case analysis

H.4 Inverse probability weighted cox proportional hazard model

For the primary composite outcome, the hazard ratio (HR) (apixaban/warfarin) was 1.23 (0.98, 1.55) overall and 1.19 (0.89, 1.60) in normal weight group, 1.09 (0.86, 1.40) in the overweight group and 1.43 (0.83, 2.48) in the obese group.

For major bleeding, the hazard ratio (HR) (apixaban/warfarin) was 0.72 (0.62, 0.83) overall and 0.98 (0.72, 1.32) in normal weight group, 0.60 (0.50, 0.72) in the overweight group and 0.67 (0.53, 0.83) in the obese group.

H.5 99% Truncated inverse probability weighting




Figure S14. 99%-truncated inverse probability weighted estimates of the 3-year BMI stratum-specific risks, risk differences per 100 people, and risk ratios of the comparative effectiveness for the total effect of apixaban versus warfarin in stroke/systemic embolism using a complete-case analysis

BMI groups	Events/No.	Risk** (95 %CI)	RR (95 %CI)	Events/No.	Risk** (95 %CI)	RR (95 %CI)		36-month Risk Ratio (95% CI
Overall	1,205/27,747	7.3 (6.8,7.8)		1,852/23,145	9.1 (8.3,9.8)		ŀ + l	0.81 (0.73,0.90)
Normal weight ≤24.9 kg/m2	359/7,669	8.6 (7.4,9.8)	0.96 (0.77,1.19)	469/5,691	9.0 (7.4,10.5)	Reference	⊢•⊣	0.96 (0.77,1.19)
Overweight 25-29.9 kg/m2	445/10,280	6.8 (6.0,7.5)	0.75 (0.61,0.93)	659/8,561	8.4 (7.2,9.6)	0.94 (0.74,1.18)	⊢⊷⊣	0.81 (0.67,0.97)
Obese ≥30 kg/m2	401/9,798	7.0 (6.2,7.7)	0.77 (0.63,0.96)	724/8,893	9.8 (8.5,11.1)	1.09 (0.87,1.37)	ŀ • -	0.71 (0.60,0.84)
Major bleeding (IPW)* BMI groups	Events/No.	Risk** (95 %CI)	RD (95 %CI)	Events/No.	Risk** (95 %CI)	RD (95 %CI)	Risk Ratio (95% CI) Favor Apixaban Fa	vor Warfarin 36-month Risk difference (95%
Major bleeding (IPW)* BMI groups	Events/No.			Events/No.			Favor Apixaban Fa	36-month
Overall	1,205/27,747	7.3 (6.8,7.8)		1,852/23,145	9.1 (8.3,9.8)		⊢	-1.8 (-2.6,-0.9)
Normal weight ≤24.9 kg/m2	359/7,669	8.6 (7.4,9.8)	-0.4 (-2.2,1.5)	469/5,691	9.0 (7.4,10.5)	Reference	├	-0.4 (-2.2,1.5)
Overweight 25-29.9 kg/m2	445/10,280	6.8 (6.0,7.5)	-2.2 (-3.9,-0.5)	659/8,561	8.4 (7.2,9.6)	-0.6 (-2.5,1.4)	⊢• −1	-1.6 (-3.0,-0.2)
Obese ≥30 kg/m2	401/9,798	7.0 (6.2,7.7)	-2.0 (-3.8,-0.3)	724/8,893	9.8 (8.5,11.1)	0.8 (-1.2,2.9)	⊢ •−1	-2.9 (-4.4,-1.4)
						-6	-5 -4 -3 -2 -1 0 1 2 Risk Difference (95% C	

Figure S15. 99%-truncated inverse probability weighted estimates of the 3-year BMI stratum-specific risks, risk differences per 100 people, and risk ratios of the comparative safety for the total effect of apixaban versus warfarin in major bleeding using a complete-case analysis